Home/Pipeline/OSE-279

OSE-279

Advanced Solid Tumors

Phase 1/2Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1/2

Status

Active

Company

OSE Immunotherapeutics

About OSE Immunotherapeutics

OSE Immunotherapeutics is an integrated, clinical-stage biotechnology company focused on developing first-in-class immunotherapies for immuno-oncology and immuno-inflammation. Its core strategy is driven by three proprietary technology platforms designed to precisely modulate the immune system. The company's most significant near-term catalyst is the Phase 3 ARTEMIA trial for Tedopi® in non-small cell lung cancer, which has received two positive IDMC recommendations. OSE aims to build value through a diversified pipeline and strategic partnerships.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Inflammation

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
NST-101 (estimated)	Novastage Pharmaceuticals	Phase 1/2	Active
Meta10-TILs	Leman Biotech	Phase 1	Active (Investigator-Initiated Trial)
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
M8891	Merck KGaA	Phase 1/2	Active
P-002	Panacea Biotec	Phase 1/2	Active
Undisclosed kinase inhibitor	Tyligand Bioscience	Phase 1	Active
TYK-001	TYK Medicines	Phase 1/2	Active
PT-112	SciClone Pharmaceuticals	Phase 1	Active - Subject Recruitment
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion